Correlation between circulating blood and microenvironment T lymphocytes in diffuse large B-cell lymphomas

Conclusions
Overall, these data suggest that DLBCL with high TME T cells display a pre-existing antitumour immune response. In the rituximab-containing regimen, TME T cells are stimulated further to participate in the immune response against lymphoma cells. In contrast, DLBCL lymphomas with low T-cell infiltration reflect the absence of a pre-existing antitumour immunity and have a lower likelihood of obtaining an optimal response to therapy.

Source: Journal of Clinical Pathology - June 17, 2022 Category: Pathology Authors: Laddaga, F. E., Ingravallo, G., Mestice, A., Tamma, R., Perrone, T., Maiorano, E., Ribatti, D., Specchia, G., Gaudio, F. Tags: Original research Source Type: research